th debilitating diseases such as cancer, multiple sclerosis, Parkinson???s, HIV/AIDS and many rare diseases,??? BIO president and CEO Jim Greenwood said.The bill provides for a 12-year data exclusivity period for biotech drugs, meaning that the Food and Drug Administration would have to wait until a biotech drug had been on the market for 12 years before it approved a biosimilar version.